News
EQS-News: Evotec SE unveils new strategy and provides 2025 guidance bolstered by strong Q4 2024 results
EQS-News: Strong start to the year: Sartorius achieves significant profitable growth in the first quarter
EQS-News: Gerresheimer: Bormioli Pharma boosts revenues and earnings
EQS-News: Evotec SE to announce results for financial year 2024 on 17 April 2025
Dr. Oz Officially Confirmed as Head of the Centers for Medicare and Medicaid Services. Here's What Retirees Need to Know So Far.
From TV star to powerful government official. That's the path taken by President Donald Trump and his new administrator of the Centers for Medicare and Medicaid Services (CMS) -- Dr. Mehmet Oz.
Oz
EQS-News: Sartorius to acquire microtissue business MatTek from Swedish BICO AB
EQS-News: First ISCC Plus certifications pave the way for renewable plastics at Sartorius
EQS-News: Sartorius AG - Resolutions of the Annual General Meeting
EQS-News: RHÖN-KLINIKUM AG once again reports a successful financial year – CEO Prof. Kaltenbach leaves the Board of Management as planned
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Explore the exciting world of Neurocrine Biosciences (NASDAQ: NBIX) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
Why HealthEquity Stock Was Sliding This Week
Over the past few days HealthEquity (NASDAQ: HQY) shares have been rather sickly. The health savings account (HSA) specialist's stock was rocked by a disappointing earnings report, and as a result
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2024 Earnings CallMar 12, 2025, 8:00 a.m. ET
Operator
Source Fool.com
EQS-News: Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb
Viatris Misses Estimates, Cash Flow Up
Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt
EQS-News: Evotec announces change in Management Board
EQS-News: Gerresheimer delivers solid results in the financial year 2024 despite market headwinds
Masimo Tops EPS, Revenue Expectations
Masimo (NASDAQ:MASI), a provider of noninvasive patient monitoring technology, released its fourth-quarter earnings for 2024, on Feb. 25, 2025. The results presented a mixed picture: strong
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
Almirall, S.A. (ALM):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223477772/en/
Almirall HQ in Barcelona (Photo: Business
Why Exelixis Stock Trounced the Market on Thursday
Cancer drug specialist Exelixis (NASDAQ: EXEL) was quite the stock market star on Friday. Following news that it's making a big, shareholder-pleasing move, market players piled into the company to
EQS-News: Sartorius releases Annual Report for 2024
Alkermes Plc EPS Soars Past Forecasts
Alkermes (NASDAQ:ALKS), a biopharmaceutical company known for its innovative drugs targeting mental health and neurological disorders, announced its Q4 2024 earnings on Feb. 12. The company reported
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Exelixis (NASDAQ: EXEL)Q4 2024 Earnings CallFeb 11, 2025, 5:00 p.m. ET
Operator
Source Fool.com
Exelixis Posts 63.7% Profit Surge
Exelixis (NASDAQ:EXEL), a biopharmaceutical company specializing in oncology treatments, released its fourth-quarter 2024 financial results, revealing a substantial rise in both revenue and
Why Neurocrine Biosciences Stock Sank Today
Despite better-than-expected profitability in the fourth quarter, which it reported late last week, Neurocrine Biosciences (NASDAQ: NBIX) hasn't been wowing analysts lately. On Monday, no less than
EQS-Adhoc: Gerresheimer AG confirms discussions with private equity investors on potential takeover offer